title: Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
abstract: Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with high human and economic burden. Novel oral anticoagulants have been approved in many markets as alternatives to warfarin for stroke prevention in patients with AF - dabigatran etexilate, apixaban and rivaroxaban. Given the high burden of AF, and given that new treatments can more effectively prevent stroke than warfarin, but at higher drug cost, there has been a need for systematic evaluation of the costs and benefits of these new treatments. In this study, we summarize the findings of a systematic literature review on the cost-effectiveness of the new oral anticoagulants. We find that there is substantial heterogeneity between the studies and their numerical findings, despite using a common set of four trials for their clinical inputs. However, there is broad consensus among them that each of the novel oral anticoagulants is cost-effective versus warfarin or aspirin.
authors: anuraag.kansal@evidera.com
authors: Anuraag R
authors: AR
authors: Kansal
authors: Ying
authors: Y
authors: Zheng
authors: Tiffany
authors: T
authors: Pokora
authors: Sonja V
authors: SV
authors: Sorensen
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D001241:Aspirin / Q000191:economics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000473:pathology*; D001562:Benzimidazoles / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D004334:Drug Administration Schedule; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000517:prevention & control; D009025:Morpholines / Q000191:economics* / Q000627:therapeutic use; D011720:Pyrazoles / Q000191:economics* / Q000627:therapeutic use; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use; D011728:Pyridones / Q000191:economics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D020521:Stroke / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013876:Thiophenes / Q000191:economics* / Q000627:therapeutic use; D054556:Venous Thromboembolism / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran; D001241:Aspirin
keywords: apixaban; atrial fibrillation; cost-effectiveness; dabigatran; rivaroxaban; stroke; warfarin